More recently there has been much interest in the hepatic effects of Tirzepatide, a GLP-1/GIP dual-agonist approved in USA for T2D treatment, that promotes reduction of liver fat content alongside significant weight loss in subjects with T2D [12]. This evidence concerns the gene GIP and type 2 diabetes mellitus.